A Pilot Study of Low-Dose Zidovudine in Human Immunodeficiency Virus Infection

Authors:
  • SBSamuel Bozzette
    Samuel Bozzette
  • RCRobert W. Coombs
    Robert W. Coombs
  • DCDennis M. Causey
    Dennis M. Causey
  • DSDavid A. Schoenfeld
    David A. Schoenfeld
  • SSStephen A. Spector
    Stephen A. Spector
  • CPCarla B. Pettinelli
    Carla B. Pettinelli
  • GDGlenn Davies
    Glenn Davies
  • DRDouglas D. Richman
    Douglas D. Richman
  • JLJohn M. Leedom
    John M. Leedom
  • PKPamela Kidd
    Pamela Kidd

Abstract
Zidovudine delays the progression of human immunodeficiency virus (HIV) infection but is associated with hematologic toxicity at high doses. Regimens are needed that preserve or enhance efficacy and reduce toxicity. Acyclovir has been reported to potentiate the effect of zidovudine on HIV in vitro.

This publication has 25 references indexed in Scilit: